Galectin Therapeutics
Business Services · Georgia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4960 Peachtree Industrial Blvd Ste 240, ...Phone Number
(678) 620-3186Website
www.galectintherapeutics.comRevenue
$37.4 MillionStock Symbol
GALTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Established in 2000, Galectin Therapeutics is headquartered in Georgia.Explore more
Galectin Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Galectin Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Galectin Therapeutics launches new products
Galectin Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Galectin Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Galectin Therapeutics has new funding data
Earning: See what the market has to say on Galectin Therapeutics recently announced quarterly report
Check out if Galectin Therapeutics is spiking on competitors!
Check if Galectin Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Galectin Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Galectin Therapeutics
Compare insights from companies similar to Galectin Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Galectin Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Galectin Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Galectin Therapeutics.
Galectin Therapeutics financials insights
Gather financial insights about Galectin Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$10M
2021
Debt
$20M
Debt
$10M
2025
Stock/Share Issuance
$10M
Galectin Therapeutics Tech Stack
A closer look at the technologies used by Galectin Therapeutics
Most Recent Scoops
Funding
Funding
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Earnings
Galectin Therapeutics News & Media
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stockGalectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise - Stock Titan
Galectin Therapeutics CMO Jamil Khurram exercised options for 568 shares at $1.23, then sold 568 shares at a $3.1004 average under a Rule 10b5-1 plan.Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30, 2026, in Barcelona, Spain.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Galectin Therapeutics
Sign Up For FreeTo access detailed company insights
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Established in 2000, Galectin Therapeutics is headquartered in Georgia.... Read More
